CONTACT US

Targeted Alpha Generator 1

TAG 1 Vision

TAG1 aims to be a premier supplier of medical radioisotopes for Targeted Alpha Therapies (TAT) that will empower biotech innovators and healthcare institutions with the technology and partnerships needed to develop groundbreaking radiopharmaceutical therapies for patients worldwide.

About TAG1

TAG 1 Inc. aims to be a premier supplier of medical radioisotopes that will be used for Radioligand Therapies (RLTs). We are actively working on providing high-purity Lead-212 isotope to innovators and biotech companies for potential drug development through partnerships.

Our proprietary portable Targeted Alpha Generator 1 (TAG1) is designed and capable of providing nuclear radiopharmacies, large hospital networks and research institutions with the ability to produce their own supply of Lead-212 isotope utilizing Radium-224 as its parent isotope, worldwide.

TAG1 Inc.

Expertise

Our team specializes in developing medical isotopes and generators which helps drive new product development and innovation in the field of radiotherapy.

Emphasis

We are focused on targeted alpha therapies (TATs) using Pb-212 to improve treatment outcomes in oncology and rare diseases. We will then focus on other isotopes like Bismuth-213 and other alpha generating isotopes.

Evolution

TAG1’s mission is to expand the horizon of cancer treatment, ultimately offering personalized and precision medicine to patients in every hospital and cancer center worldwide.

TAG1 Highlights

We offer small biotech and pharmaceutical companies a critical advantage by providing reliable access to high-purity Lead-212 isotopes. Our proprietary technology enables companies to produce their own supply of isotopes, ensuring consistency and reducing reliance on external sources. 

By partnering with us, companies can accelerate their pre-clinical and clinical programs, optimize their R&D timelines, and enhance their potential for groundbreaking discoveries in cancer treatment.

By integrating our innovative technology with existing distribution channels we can ensure seamless delivery of medical isotopes to our partners. Collaborating closely with nuclear radiopharmacies and research institutions allows us to establish robust logistical frameworks that guarantee reliable, On Time And In-Full (OTIF) delivery. 

This coalescence ensures that our high-purity Lead-212 isotopes reach the point of care without disruption, empowering clinicians and researchers to advance their therapeutic programs efficiently.

There is an increasing demand for our scalable solutions in cancer treatment, and we are well-prepared to meet this expanding need in the medical field.

We have the capacity to scale our production to meet increasing market demands.

We are geared to be an early entrant in clinical supply of Lead-212 isotope with our advanced scalable isotope technology and proprietary generator

TARGETED ALPHA THERAPY

Our TAG 1 Generator Produces Pb-212 Isotopes for Targeted Alpha Therapy.

Targeted alpha therapy (TAT) is a type of radioligand therapy that uses isotopes that undergo alpha decay to destroy cancer cells. TAT has the potential to provide highly targeted treatments to tumorous cells, allowing the targeting of common cancers including prostate, NETs and pancreatic cancer.

 

Read More

Executive Management

Sumit Verma

Chief Executive Officer, TAG1 Inc.

Read BIO

Board of Directors

Dr. Carolyn Anderson

Director MIZZOU Theranostics Center

Castor Armesto

General Counsel Earthrise Energy

Dimitrios Mantzilas

CTO Precirix

Dr. Rahul Singhvi

Co-founder & CEO Resilience

Press

View All Press Releases

CONTACT US

Contact Info

Subscribe to our newsletter

Developed by: MBI

TAG1 INC 2025

Targeted Alpha Therapy (TAT) is an advanced form of radiotherapy designed to selectively target and destroy cancer cells using alpha-emitting isotopes. This innovative treatment works by attaching an alpha-emitting radionuclide, such as Lead-212 or Actinium-225, to a targeting molecule, like an antibody or peptide. 

These targeting molecules are engineered to bind specifically to cancer cells or cancer-associated antigens for precise delivery. Once bound to the cancer cells, the alpha particles emit high-energy radiation directly into the cancer cells. The short range of the alpha particles confines the radiation to the targeted area, minimizing damage to surrounding healthy tissue. 

This method targets cancer cells with precision, making TAT particularly effective against micrometastases — small clusters of cancer cells that have spread from the primary tumor site. TAT reduces the risk of collateral damage to healthy tissues, leading to fewer side effects compared to conventional therapies. 

Moreover, the high potency of alpha particles can induce cell death in even radioresistant cancer cells. TAT’s versatility allows it to be applied to various types of cancers, including those difficult to treat with traditional methods, such as metastatic and hematological malignancies. Overall, TAT provides a promising treatment option for patients with challenging or advanced-stage cancers.

Sumit Verma is the founding Chief Executive Officer (CEO) for TAG1 inc. – a premier supplier of medical radioisotopes that will be used for Radioligand Therapies (RLTs). He also serves as co-founder of Orchestra Life Sciences, a technical advisory team that is in the forefront of providing scientific and strategic support in the development and commercialization of advanced therapies for cancer and rare diseases.

He most recently served as Senior Vice President Global Strategy and Manufacturing for Iovance Biotherapeutics where he had executive responsibilities for building a new cell therapy manufacturing facility, the Iovance Cell Therapy Center (iCTC), in The Navy Yard Philadelphia. He formed the commercial manufacturing organization at iCTC that has achieved significant milestones including the accelerated FDA approval of Amtagvi ™ – the world’s 1st approved solid tumor cell therapy.

Verma has successfully built and led technical and manufacturing organization for five FDA-approved therapeutic launches over the past 25 years: AMTAGVI™, Ultra-Technekow™ V4 (Technetium Tc 99m) Generator, Sestamibi™, Proquad Vaccine ™ and Detectnet™ . He has also led teams in the development and launch of Xenon-133 Gas, Germanium-68, LEU Molybdenum-99 and I-123 gas medical isotopes.

Prior to Iovance, he has had multiple leadership roles at Merck and Co., Covidien, Mallinckrodt and served as the Chief Operating Officer (COO) for Curium Pharmaceuticals. Sumit received his Bachelor of Science in Chemical Engineering from Lafayette College and Masters in Engineering from Washington University in St. Louis.